Recent REVB News
- Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders • ACCESS Newswire • 05/11/2026 01:00:00 PM
- Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 • ACCESS Newswire • 05/07/2026 08:15:00 PM
- Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board • ACCESS Newswire • 04/06/2026 01:00:00 PM
- Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study • ACCESS Newswire • 03/30/2026 01:00:00 PM
- Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference • ACCESS Newswire • 03/24/2026 01:00:00 PM
- Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference • ACCESS Newswire • 03/19/2026 01:00:00 PM
- Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 • ACCESS Newswire • 02/26/2026 09:15:00 PM
- Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 • ACCESS Newswire • 01/26/2026 02:55:00 PM
- Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds • ACCESS Newswire • 01/23/2026 07:10:00 PM
- Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI • ACCESS Newswire • 01/21/2026 01:30:00 PM
- Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) • ACCESS Newswire • 01/14/2026 02:00:00 PM
- Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • ACCESS Newswire • 01/12/2026 10:00:00 PM
- Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development • ACCESS Newswire • 01/07/2026 02:00:00 PM
- Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting • ACCESS Newswire • 12/01/2025 02:00:00 PM
- Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year • ACCESS Newswire • 11/20/2025 02:00:00 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 • ACCESS Newswire • 11/06/2025 09:15:00 PM
- Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date • ACCESS Newswire • 10/29/2025 01:00:00 PM
- Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 • ACCESS Newswire • 10/15/2025 09:00:00 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025 • Business Wire • 08/08/2025 10:30:00 AM
- Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research • Business Wire • 07/24/2025 01:00:00 PM
- Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study • Business Wire • 07/16/2025 01:00:00 PM
- Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 • Business Wire • 07/01/2025 09:26:00 PM
- Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering • Business Wire • 05/29/2025 08:05:00 PM
- Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering • Business Wire • 05/29/2025 12:00:00 PM
